by Madaline Spencer | Jun 24, 2025
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. Bullous pemphigoid is a rare autoimmune, skin disorder characterized by large blisters usually located on the arms, legs, or...
by Madaline Spencer | Jun 24, 2025
Aravindhan Veerapandiyan, MD, Pediatric Neuromuscular Neurologist at Arkansas Children’s Hospital, discusses new data from the EMBARK part 2 study of Elevidys (delandistrogene moxeparvovec) in patients with Duchenne muscular dystrophy (DMD). DMD is a...
by Madaline Spencer | Jun 23, 2025
Gideon Hirschfield, MD, of the Toronto General Hospital and Toronto Centre for Liver Disease, discusses results from the phase 3 GLISTEN trial in patients with primary biliary cholangitis (PBC). PBC is a chronic, progressive autoimmune liver disease in...
by Madaline Spencer | Jun 20, 2025
Claudia Sommer, MD, Professor of Neurology at the University of Würzburg, Germany, and Alex Seluzhytsky, MD, Senior Global Medical Director at Sanofi, discuss data on riliprubart for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). ...
by Madaline Spencer | Jun 19, 2025
Salomon Manier, MD, PhD, Associate Professor of Hematology at Lille University Hospital in France, discusses results from a phase 1b clinical trial evaluating linvoseltamab combination therapy in patients with relapsed/refractory multiple myeloma (MM). ...
